# Leora Horn

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/leora-horn-2/

## Facts

| Field | Value |
| --- | --- |
| Citations | 55,733 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 53 |
| i10-index | 117 |
| OpenAlex ID | https://openalex.org/A5103102157 |
| Works | 203 |

## Researcher papers

Showing 12 of 13.

- [Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer](https://scholariq.org/papers/safety-activity-and-immune-correlates-of-anti-pd-1-antibody-in-cancer/)
- [Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer](https://scholariq.org/papers/nivolumab-versus-docetaxel-in-advanced-nonsquamous-non-small-cell-lung-cancer/)
- [Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer](https://scholariq.org/papers/pembrolizumab-for-the-treatment-of-non-small-cell-lung-cancer/)
- [First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer](https://scholariq.org/papers/first-line-nivolumab-in-stage-iv-or-recurrent-non-small-cell-lung-cancer/)
- [Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial](https://scholariq.org/papers/activity-and-safety-of-nivolumab-an-anti-pd-1-immune-checkpoint-inhibitor-for/)
- [Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer](https://scholariq.org/papers/overall-survival-and-long-term-safety-of-nivolumab-anti-programmed-death-1/)
- [NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 1.2020](https://scholariq.org/papers/nccn-guidelines-insights-non-small-cell-lung-cancer-version-1-2020/)
- [Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)](https://scholariq.org/papers/nivolumab-versus-docetaxel-in-previously-treated-patients-with-advanced-non/)
- [Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: Results From the CA209-003 Study](https://scholariq.org/papers/five-year-follow-up-of-nivolumab-in-previously-treated-advanced-non-small-cell/)
- [NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 4.2016](https://scholariq.org/papers/nccn-guidelines-insights-non-small-cell-lung-cancer-version-4-2016/)
- [Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: CheckMate 153](https://scholariq.org/papers/continuous-versus-1-year-fixed-duration-nivolumab-in-previously-treated-advanced/)
- [Satisfaction With Work-Life Balance and the Career and Retirement Plans of US Oncologists](https://scholariq.org/papers/satisfaction-with-work-life-balance-and-the-career-and-retirement-plans-of-us/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.